BioCentury This Week
BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.
For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.
Episodes
299 episodes
Ep. 289 - Replacing Animal Models. Plus: RFK Jr. & FDA
FDA’s plan to move away from animal toxicity testing could expedite INDs and cut costs for biopharma companies, while helping the U.S. maintain its position as a clinical research hub. On ...
•
Season 6
•
Episode 289
•
36:55
Ep. 288 - FDA and Tariffs Turmoil, and AACR Preview
Loss of leadership, cuts to staffing and a proposed reorganization at FDA have heightened biotech risk amid an already turbulent mac...
•
Season 6
•
Episode 288
•
26:34
Ep. 287 - The Bear is Back: Marks’ Ouster, Tariffs and a Tumbling XBI
Biotech indexes are tumbling after one of FDA’s last veteran leaders was pushed out by HHS Secretary RFK Jr. and the threat of tariffs weigh on a key biotech index. On the latest BioCentury This Week podcast, BioCentury’s editors discu...
•
Season 6
•
Episode 287
•
25:46
Ep. 286 - Sofinnova’s Pan-European Accelerator, China Biotechs, Trump Tariffs
European venture firm Sofinnova Partners is expanding the reach of its Biovelocita accelerator beyond Italy to stretch across the greater continent. On the latest BioCentury This Week podcast, BioCentury’s editors
•
Season 6
•
Episode 286
•
24:30
Ep. 285 - BIO's Trump 2.0 Plan. Plus: Autoimmune CAR Ts & Telix's Radiopharma Play
BIO is engaging with President Donald Trump to protect and improve FDA. It’s also hoping biopharmas can dodge tariffs and find paths to modify the Inflation Reduction Act and reinstate pediatric priority review vouchers. On the latest BioCentur...
•
Season 6
•
Episode 285
•
28:26
Ep. 284 - Takeaways from the East-West Summit
While the culling of companies in the biotech bear market may have yet to subside, creative cross-border deal-making on innovative assets is spreading across Asia’s Arc of Innovation. Sciwind Biosciences Co. Ltd.’s Jing Shu and A*Star’s Lisa Oo...
•
Season 6
•
Episode 284
•
41:27
Ep. 283 - Makary’s FDA Agenda, Amylin in Obesity and Life After DEI
The almost certain confirmation of Marty Makary as FDA commissioner this month will cap a transition marked by internal upheaval and political infighting. On the latest BioCentury This Week podcast, BioCentury’s editors discuss Thursday’s
•
Season 6
•
Episode 283
•
31:30
Ep. 282 - CRISPR Lessons: Plus, AbbVie Enters Obesity
The track record of biotechs launched to create curative therapies using CRISPR-Cas9 provides new insights into the old debate over whether platform companies should validate their technology on established targets or pursue new ones. On the la...
•
Season 6
•
Episode 282
•
23:46
Ep. 281 - Roche Reboot and 5 Things on Trump 2.0
Once pharma’s oncology powerhouse, Roche is charting a new course that extends beyond its traditional stronghold in cancer therapeutics. On the latest BioCentury This Week podcast...
•
Season 6
•
Episode 281
•
22:12
Ep. 280 - China Competition. Plus: FDA Firings and Biotech IPOs
Rather than fretting over increasing competition from Chinese life sciences companies, biotechs in the U.S. should rise to the challenge and learn from their competitors. On the latest BioCentury This Week podcast, BioCentury’s editors...
•
Season 6
•
Episode 280
•
27:52
Ep. 279 - East-West Summit Preview
Western VCs are paying more attention than ever to innovation emerging from Asia — from antibody-drug conjugates to bispecifics, AI and beyond — as the NewCo Model becomes the latest trend to bridge talent, assets and venture money across the P...
•
Season 6
•
Episode 279
•
29:54
Ep. 278 - Trump 2.0’s Impact on FDA, NIH. Plus: Precision Medicine
White House plans to slash FDA and NIH risk decimating two agencies at the core of U.S. biomedical innovation. On the latest BioCentury This Week podcast, BioCentury’s editors assess<...
•
Season 6
•
Episode 278
•
26:14
Ep. 277 - Asia's NewCo Model, FDA Tipping Point, Vertex's Pain Drug
The boom in the creation of companies that were launched in the West based on assets sourced in Asia signals China’s galloping speed of innovation. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the “
•
Season 6
•
Episode 277
•
25:03
Ep. 276 - Precision Neuropsychiatry Spotlight With ICON's Peter Schueler
Psychiatric drug development has had major wins over the past year-and-a-half — think Karuna Pharmaceuticals' $14 billion takeout by Bristol Myers Squibb and the subsequent launch of a new schizophrenia therapy — but targeted neuropsychiatric d...
•
Season 6
•
Episode 276
•
21:07
Ep. 275 - Series As & Innovation. Plus: Rocky Transition at FDA, NIH
BioCentury’s analysis of the technologies behind last year’s biotech series A raisers sees progress in nanoparticles, CAR cell therapies, degraders and antibody-drug conjugates. On the latest BioCentury This Week podcast, BioCentury’s ...
•
Season 6
•
Episode 275
•
33:09
Ep. 274 - 2025 Biotech Preview: Markets, Catalysts and AI
With political uncertainty overshadowing market sentiment going into 2025, BioCentury’s editorial team assesses the bull and bear arguments for biotech in the New Year on the BioCentury This Week podcast’s
•
Season 6
•
Episode 274
•
36:21
Ep. 273 - JPM 2025 Wrap: Sunny Skies & Megarounds
Sunshine and a stream of deals brightened the mood at this year’s J.P. Morgan Healthcare Conference, offering a pleasant counterpoint to continued pessimism over the state of the capital markets. On the latest BioCentury This Week podc...
•
Season 6
•
Episode 273
•
22:21
Ep. 272 - JPM Deal Buzz & Rep. Auchincloss’ Take on Biopharma
J&J’s $14.6 billion takeout of neurology play Intra-cellular Therapies headlined a buzzy start to the J.P. Morgan Healthcare Conference, where a flurry of deal announcements recalled the conference’s pre-pandemic days. On the latest Bio...
•
Season 6
•
Episode 272
•
27:29
Ep. 271 - Biotech in the New Year. Plus: Beyond Biosecure
Can biotech break free of the macro factors that have buffeted the industry of late? On the first BioCentury This Week podcast of 2025, BioCentury’s editors offer their predictions for the...
•
Season 6
•
Episode 271
•
34:54
Ep. 270 - Temple’s FDA Legacy. Plus: Chinese Innovation & Novo Obesity Data
Preview: In his five decades at FDA, Robert “Bob” Temple helped revolutionize the ways medical products are developed and regulated. On the latest BioCentury This Week podcast, Washington Editor Steve Usdin reflects on the
•
Season 5
•
Episode 270
•
34:56
Bonus Content - Trends in Global Biopharma Deals: Lazard’s Kingston and Raine
With most of the highly attractive late-stage assets already scooped up, pharmas are turning their sights to Phase II companies, and lining up their case to make an attractive offer and move fast. About 40% of the M&A deals in 2023-24 were ...
•
Season 5
•
34:54
Ep. 269 - Trends in VC Funds, Obesity Start-ups and More
Lately, it appears some biotech VCs have hit a ceiling, capping their new funds at or below the amount of their previous vehicles, says Paul Bonanos on the latest BioCentury This Week. Bonanos and his BioCentury editorial colleagues
•
Season 5
•
Episode 269
•
33:14
Ep. 268 - Biosecure Setback & Novartis' $1B PTC Deal
A pair of lawmakers have dealt the Biosecure Act a setback that could derail the legislation, even as Congress continues its push to reduce reliance on China in the life sciences. On the latest BioCentury This Week podcast, Washington Editor St...
•
Season 5
•
Episode 268
•
21:49
Ep. 267 - Trump's NIH Pick & Multi-targeted CAR Ts
On the latest BioCentury This Week podcast, Washington Editor Steve Usdin and colleagues discuss how President-elect Donald Trump’s pick to lead NIH, Jay Bhattacharya, would lead NIH and how that could affect the biopharma industry.
•
Season 5
•
Episode 267
•
27:26
Ep. 266 - Jefferies Recap, FDA Commissioner & Biosecure Update
Positive vibes about biotech emanating from the Jefferies Healthcare Conference were overshadowed by the uncertainty that is ahead because of the result of the U.S. elections. On the latest BioCentury This Week, BioCentury’s editors di...
•
Season 5
•
Episode 266
•
26:32
